Clinical trial
Atazanavir Twice Daily
NCT00357721 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00357721 |
|---|---|
| Title | Atazanavir Twice Daily |
| Official title | Randomized, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics of Atazanavir Administered Twice-Daily in Health Subjects |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, Protease Inhibitor |
| Intervention type | Drug |
| Interventions | Atazanavir Sulphate |
| Enrollment | 18 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Jul 27, 2006 |
| Last update posted | Apr 6, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: